Evidence map›Paper›PMID 26087860›Full record

ReviewGut and liver2015

Management of Hepatocellular Carcinoma: Current Status and Future Directions.

Jennifer S Au, Catherine T Frenette

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gut and liver, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. PCAT-1: A Novel Oncogenic Long Non-Coding RNA in Human Cancers.International journal of biological sciences · 2019
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. New concepts in embolotherapy of HCC.Medical oncology (Northwood, London, England) · 2017
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Jennifer S AuDivision of Gastroenterology and Hepatology, Scripps Clinic.
Catherine T FrenetteLiver Transplantation, Center for Organ and Cell Transplantation, Scripps Clinic, La Jolla, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the second most common cause of cancer death worldwide. This cancer commonly arises against a background of chronic liver disease. As a result, a patient with HCC requires multidisciplinary care. Treatment options vary widely based on tumor burden and metastases. The most widely utilized staging system is the Barcelona Clinic Liver Cancer staging system, which recommends treatments based on tumor size and the underlying liver disease and functional status of the patient. Treatment options range from surgical resection or transplantation to locoregional therapies with modalities such as radiofrequency ablation and transarterial chemoembolization to systemic chemotherapies. Future care involves the development of combination therapies that afford the best tumor response, further clarification of the patients best suited for therapies and the development of new oral chemotherapeutic agents.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularCatheter AblationChemoembolization, TherapeuticCombined Modality TherapyForecastingHumansLiver NeoplasmsLiver TransplantationNeoplasm StagingAntineoplastic AgentsCarcinoma, hepatocellularRadiofrequency ablationSorafenibStaging systemsTransarterial chemoembolization

Identifiers

PMID26087860
PMCPMC4477987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.